Multi-Year Study Conducted with Amgen Identified Mutations in KRAS / NRAS (RAS) Exons in Tumors from Metastatic Colorectal Cancer Patients using Sanger Sequencing

OMAHA, Neb. (October 13, 2015) — Transgenomic, Inc. (NASDAQ: TBIO) today announced that it presented a poster last week at CAP ’15, the annual meeting of the College of American Pathologists. The poster, which was co-authored by researchers from Transgenomic and Amgen, reported on the results of analysis of tumor tissue from two randomized clinical trials using Sanger sequencing. The analysis concluded that the use of validated assays, relevant controls, and assay-specific tissue requirements resulted in highly reproducible Sanger sequencing data from the FFPE clinical specimens.1

Transgenomic provided pharmacogenomic services that included identification of mutations in KRAS exons 3 & 4 / NRAS exons 2-4 (collectively, RAS) in more than 2000 metastatic colorectal cancer patients. The focus of this analysis was to determine whether accuracy of detection of RAS mutations is affected by analytical methods and sample preparation.

Katherine Richardson, PhD, Transgenomic Vice President of Research & Development, noted, “This multi-year project conducted with our colleagues at Amgen is a good example of how Transgenomic can work with our biopharmaceutical clients to generate data relevant to actionable mutations. In this project, we obtained reproducible data from patient FFPE tissue samples using Sanger sequencing. This analysis generated data that contributes to the advancement of personalized medicine.”

1 Extended RAS Mutation Testing in Metastatic colorectal cancer. Catherine Lofton-Day, Scott D. Patterson, Benjamin L. Legendre Jr., Katherine Richardson, CAP ’15, Nashville, TN, October 5, 2015.

For information on Transgenomic’s Biomarker Discovery services, click here. For information about its EGFR CLIA tests, click here.

About Transgenomic
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR™ and its unique genetic tests provided through its Patient Testing business. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These forward-looking statements include statements relating to Transgenomic’s revitalization and asset monetization strategy, the potential applications for Multiplexed ICE COLD-PCR™, the availability of cash for commercialization efforts and the expected timing for its asset monetization strategy. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic’s filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Contacts:

Media:
BLL Partners LLC
Barbara Lindheim
212-584-2276
blindheim@bllbiopartners.com

Investors:
Transgenomic Investor Relations
investor.relations@transgenomic.com